Medinol today announced the successful first-in-human implantation of its ChampioNIR drug-eluting peripheral stent.

The stent incorporates a drug-release mechanism that enables delivery of a 'limus' medication throughout peripheral arteries.

Premature discontinuation of antiplatelet therapy is the most important predictor of stent thrombosis; therefore, patients who are candidates for implantation of drug-eluting stents should be ...

InspireMD (Nasdaq:NSPR) announced today that the FDA granted investigational device exemption (IDE) for its CGuard Prime ...

Novel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES) as they ...

Medinol Ltd. announced the first-in-human (FIH) implantation of the ChampioNIR drug-eluting peripheral stent. The procedure w ...

The peripheral vascular devices market is set to grow significantly, reaching an estimated USD 14.73 billion by 2029 from USD ...

However, platelet reactivity to clopidogrel is variable and stent thrombosis can occur suddenly and unexpectedly in up to 3% of patients. Is responsiveness to clopidogrel an indicator of risk of ...

Pre (A) and postintervention (B) angiographic images of a recurrent CoAo treated with Minima stent implantation in a 5 month old, 5.9 kg infant. Credit: Catheterization and Cardiovascular ...

Figure 1. Treatment algorithm for CLTI and complex lesions. *IVL, intravascular lithotripsy.